Lenacapavir: A Global Breakthrough in HIV Prevention and the Ethical Imperative of Equitable Access - A Literature Review
MEDICUS · 2025-12 · 9 (2) · 51-67
DOI: 10.58944/zxas9849 ↗Kurz gefasst
Fachartikel in der Zeitschrift MEDICUS, 2025-11. Verfasst von Eljo PAJA und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Since the early 1980s, the global HIV epidemic has posed persistent challenges to prevention efforts. Despite the progress achieved through oral preexposure prophylaxis (PrEP), adherence issues, stigma, and limited access have hindered its widespread success. Lenacapavir, a long-acting capsid inhibitor, represents a breakthrough innovation that offers six months of continuous protection through a single subcutaneous injection, that would potentially transform HIV prevention worldwide.
Aim
This study aims to evaluate the clinical effectiveness, safety, and global impact of lenacapavir as a new generation PrEP agent.Methodology: We conducted a literature review that was primarily based on results from a systematic literature review and meta-analysis that included 26 international sources, including The New England Journal of Medicine, Nature, and The Lancet. Data from the PURPOSE-1 and PURPOSE-2 trials were also reviewed comparatively to assess the drug’s efficacy, side effects, and population outcomes, while descriptive statistics illustrated predicted epidemiological trends.
Results
The major finding has derived from the meta-analyses showing that lenacapavir had an extremely high (99,9%) efficacy in preventing HIV infection among participants using it, with a significantly lower rate of adverse events compared to oral PrEP regimens. Global modelling studies predict up to a 60% reduction in new HIV infections by 2030 if lenacapavir is implemented more widely, especially in Sub-Saharan Africa.
Conclusions
Lenacapavir represents a paradigm shift in HIV prevention, combining scientific innovation with public health equity. If affordability and access barriers are addressed, this treatment may become a cornerstone of global HIV elimination strategies in the future.
Zitieren
APA
PAJA, E., MERKURI, L., & SHAPO, L. (2025). Lenacapavir: A Global Breakthrough in HIV Prevention and the Ethical Imperative of Equitable Access - A Literature Review. MEDICUS, 9(2), 51-67. https://doi.org/10.58944/zxas9849
Vancouver
PAJA E, MERKURI L, SHAPO L. Lenacapavir: A Global Breakthrough in HIV Prevention and the Ethical Imperative of Equitable Access - A Literature Review. MEDICUS. 2025;9(2):51-67. doi:10.58944/zxas9849
BibTeX
@article{PAJA2025,
author = {PAJA, Eljo and MERKURI, Lumturi and SHAPO, Leidon},
title = {Lenacapavir: A Global Breakthrough in HIV Prevention and the Ethical Imperative of Equitable Access - A Literature Review},
journal = {MEDICUS},
year = {2025},
volume = {9},
number = {2},
pages = {51--67},
doi = {10.58944/zxas9849}
}
EUVIMED